ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1939

Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study

Farzin Khosrow-Khavar, Seoyoung Kim, Hemin Lee, Su Been Lee and Rishi Desai, Brigham and Women's Hospital, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Cardiovascular, Disease-Modifying Antirheumatic Drugs (Dmards), Pharmacoepidemiology, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Abstracts: RA – Treatments I: Safety & Harms (1939–1942)

Session Type: Abstract Session

Session Time: 4:00PM-4:15PM

Background/Purpose: Recent reports from a post-marketing safety trial, “ORAL Surveillance”, indicated an increased risk of cardiovascular (CV) outcomes in RA patients treated with tofacitinib. Thus, the aim of this study was to examine the risk of CV outcomes associated with tofacitinib, compared with tumor necrosis factor inhibitors (TNFI), in patients with RA.

Methods: Using U.S. claims data from ‘Optum’ Clinformatics (2012-2020), IBM ‘MarketScan’ (2012-2018), and Medicare (parts A, B, and D, 2012-2017) databases, we created two study cohorts of RA patients initiating treatment with tofacitinib or TNFI: 1) A restrictive “RCT-duplicate cohort” mimicking inclusion/exclusion criteria of the ORAL Surveillance trial to calibrate our findings against trial results, 2) a broader “real-world evidence (RWE) cohort” including representative population from routine care. Patients were followed from treatment initiation for study outcomes until treatment discontinuation or switch, insurance disenrollment, death, or end of the study period. The primary composite CV outcome, was defined using inpatient claims for myocardial infarction or stroke. Cox proportional hazards models with propensity score fine-stratification weighting were used to generate hazard ratios (HR) and 95% confidence intervals (CI) and accounted for over 60 potential confounders in each of the datasets. Fixed effects models with inverse variance were used to pool database-specific effect estimates. Secondary analysis was conducted by baseline cardiovascular disease (RWE cohorts only).

Results: In RWE study population, 28,568, 34,083, and 39,612 patients were identified from Optum, MarketScan, and Medicare, respectively, of whom 13.2%, 15.6%, and 9.5% initiated treatment on tofacitinib. The mean age was 55, 53, and 72 years in Optum, MarketScan, and Medicare, respectively. In RWE cohort, 13% of patients in Optum, 10% in MarketScan, and 31% in Medicare had a history of cardiovascular disease. The crude incidence rates of the primary CV endpoint per 100 person-years (95% CI) for tofacitinib and TNFI users were 0.73 (0.47-1.09) and 0.61 (0.51-0.72) in Optum; 0.75 (0.52-1.05) and 0.52 (0.44-0.61) in MarketScan; and 2.14 (1.66-2.70) and 1.86 (1.71-2.02) in Medicare. Overall, in the RWE cohort, the pooled HR (95% CI) for CV outcomes comparing tofacitinib with TNFI was 1.01 (0.83-1.23). Results from the RCT-duplicate cohort were in alignment with reports from the ORAL Surveillance trial (pooled HR: 1.24, 95% CI: 0.90-1.69 vs trial: 1.33, 95% CI: 0.91-1.94). Among RWE patients with baseline cardiovascular disease, the pooled HR (95% CI) was 1.27 (0.95-1.70). Consistent results were observed across other secondary and sensitivity analyses.

Conclusion: This multi-database large population-based study did not find evidence for an increased risk of CV outcomes with tofacitinib, in comparison with TNFI, in the overall RA patient population treated in the real-world setting. However, similar to the reported results from ORAL Surveillance trial, tofacitinib, in comparison with TNFI, was associated with an increased, but statistically non-significant, risk of CV outcomes in RA patients with CV risk factors or a history of cardiovascular disease.

Figure. Risk of composite CV outcomes when comparing tofacitinib with TNF inhibitors (reference) in patients with RA.


Disclosures: F. Khosrow-Khavar, None; S. Kim, AbbVie, 5, Roche, 5, Pfizer, 5, Bristol-Myers Squibb, 5; H. Lee, None; S. Lee, None; R. Desai, Bayer, 5, Vertex Pharmaceuticals, 5, Novartis, 5.

To cite this abstract in AMA style:

Khosrow-Khavar F, Kim S, Lee H, Lee S, Desai R. Risk of Cardiovascular Outcomes in Patients Treated with Tofacitinib: First Results from the Safety of TofAcitinib in Routine Care Patients with Rheumatoid Arthritis (STAR-RA) Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/risk-of-cardiovascular-outcomes-in-patients-treated-with-tofacitinib-first-results-from-the-safety-of-tofacitinib-in-routine-care-patients-with-rheumatoid-arthritis-star-ra-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-cardiovascular-outcomes-in-patients-treated-with-tofacitinib-first-results-from-the-safety-of-tofacitinib-in-routine-care-patients-with-rheumatoid-arthritis-star-ra-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology